Healthcare · Biotechnology
Price
$7.00
Market Cap
$449.4M
Employees
106
Beta
0.39
Avg Volume
557,570
CEO
Elisabet de los Pinos
Business Description
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-3.98
Stock Price: $7.00
EPS (Diluted): -1.76
EPS (Diluted): -1.76
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.40
Stock Price: $7.00
Total Equity: $136.91M
Shares: 60,337,608
Total Equity: $136.91M
Shares: 60,337,608
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-3.43
Market Cap: $449.40M
Total Debt: $14.13M
Cash: $59.52M
EBITDA: -$104.95M
Total Debt: $14.13M
Cash: $59.52M
EBITDA: -$104.95M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$286.7M
Market Cap: $449.40M
Total Debt: $14.13M
Cash: $59.52M
Total Debt: $14.13M
Cash: $59.52M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $7.00
Revenue: $0.00
Shares: 60,337,608
Revenue: $0.00
Shares: 60,337,608
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$112.79M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$106.19M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-78.1%
Net Income: -$106.19M
Total Equity: $136.91M
Total Equity: $136.91M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-95.5%
Operating Income: -$112.79M
Tax Rate: -0.1%
Equity: $136.91M
Total Debt: $14.13M
Cash: $59.52M
Tax Rate: -0.1%
Equity: $136.91M
Total Debt: $14.13M
Cash: $59.52M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
8.15
Current Assets: $149.74M
Current Liabilities: $18.38M
Current Liabilities: $18.38M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.10
Short-Term Debt: $0.00
Long-Term Debt: $14.13M
Total Debt: $14.13M
Total Equity: $136.91M
Long-Term Debt: $14.13M
Total Debt: $14.13M
Total Equity: $136.91M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 60,337,608
Shares: 60,337,608
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.27
Total Equity: $136.91M
Shares: 60,337,608
Shares: 60,337,608
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.41
Operating CF: -$84.74M
CapEx: -$447,000
Shares: 60,337,608
CapEx: -$447,000
Shares: 60,337,608
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $7.00
Stock Price: $7.00
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$106.19M
Net Income: -$106.19M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AURA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 5:09pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $1.3M | $0 | $0 |
| Gross Profit | $0 | $0 | -$1.3M | $0 | $0 |
| Operating Expenses | $35.3M | $60.3M | $83.7M | $96.1M | $112.8M |
| Operating Income | -$35.3M | -$60.3M | -$85.0M | -$96.1M | -$112.8M |
| Net Income | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106.2M |
| EBITDA | -$34.4M | -$57.6M | -$75.0M | -$85.6M | -$105.0M |
| EPS | $-1.58 | $-1.96 | $-1.93 | $-1.75 | $-1.76 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 5:09pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $149.1M | $121.6M | $41.1M | $31.7M | $59.5M |
| Total Current Assets | $153.7M | $196.7M | $231.8M | $160.6M | $149.7M |
| Total Assets | $160.0M | $223.9M | $255.1M | $182.5M | $169.4M |
| Current Liabilities | $7.4M | $10.5M | $12.4M | $14.9M | $18.4M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $14.1M |
| Total Liabilities | $7.7M | $28.4M | $29.2M | $30.5M | $32.5M |
| Total Equity | $152.3M | $195.6M | $225.8M | $152.0M | $136.9M |
| Retained Earnings | -$152.1M | -$210.9M | -$287.3M | -$374.2M | -$480.4M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 5:09pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$32.4M | -$54.6M | -$63.8M | -$79.8M | -$84.7M |
| Capital Expenditure | -$2.1M | -$1.1M | $-709,000 | -$1.3M | $-447,000 |
| Free Cash Flow | -$34.5M | -$55.7M | -$64.6M | -$81.1M | -$85.2M |
| Acquisitions (net) | $0 | $66,775 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $131.7M | -$26.8M | -$80.5M | -$9.4M | $27.8M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 7:47am (2h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$7.7M $7.7M – $7.7M
|
$28.3M $28.3M – $28.3M
|
$108.4M $108.4M – $108.4M
|
$171.2M $171.2M – $171.2M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$100.3M -$116.2M – -$84.4M
|
-$92.0M -$96.5M – -$87.5M
|
-$66.4M -$66.4M – -$66.4M
|
-$42.5M -$42.5M – -$42.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 5:09pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | +100.0% | — |
| Operating Income Growth | -71.0% | -41.0% | -13.1% | -17.3% |
| Net Income Growth | -66.7% | -30.0% | -13.8% | -22.2% |
| EBITDA Growth | -67.4% | -30.2% | -14.1% | -22.6% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 7:47am (2h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Gibney Anthony S | S-Sale | 12,824.00 | $6.42 | $82,330 |
| 2026-06-11 | Bitetti Teresa Marie | A-Award | 15,000.00 | $0.00 | $0 |
| 2026-06-11 | Bitetti Teresa Marie | A-Award | 30,000.00 | $6.21 | $186,300 |
| 2026-06-11 | Srivastava Sapna | A-Award | 15,000.00 | $0.00 | $0 |
| 2026-06-11 | Srivastava Sapna | A-Award | 30,000.00 | $6.21 | $186,300 |
| 2026-06-11 | Johnson David Michael | A-Award | 15,000.00 | $0.00 | $0 |
| 2026-06-11 | Johnson David Michael | A-Award | 30,000.00 | $6.21 | $186,300 |
| 2026-06-11 | Mattessich Antony C. | A-Award | 15,000.00 | $0.00 | $0 |
| 2026-06-11 | Mattessich Antony C. | A-Award | 30,000.00 | $6.21 | $186,300 |
| 2026-05-19 | Holles Natalie C. | A-Award | 2,169,103.00 | $7.39 | $16.0M |
| 2026-05-19 | Holles Natalie C. | A-Award | 553,844.00 | $0.00 | $0 |
| 2026-05-19 | Holles Natalie C. | A-Award | 600,118.00 | $0.00 | $0 |
| 2026-05-07 | Matrix Capital Management Company, LP | S-Sale | 6,922,870.00 | $5.64 | $39.0M |
| 2026-04-30 | Holles Natalie C. | 0.00 | $0.00 | $0 | |
| 2026-04-16 | Kilroy Conor | S-Sale | 11,738.00 | $7.02 | $82,401 |
| 2026-03-02 | Kilroy Conor | A-Award | 62,339.00 | $0.00 | $0 |
| 2026-03-02 | Kilroy Conor | A-Award | 112,661.00 | $6.14 | $691,739 |
| 2026-03-02 | Gibney Anthony S | A-Award | 71,245.00 | $0.00 | $0 |
| 2026-03-02 | Gibney Anthony S | A-Award | 128,755.00 | $6.14 | $790,556 |
| 2026-03-02 | de los Pinos Elisabet | A-Award | 166,000.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for AURA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for AURA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30